Dr. Amin focuses on developing innovative analytical methods for pre-clinical drug development, encompassing both small and large molecules. He specializes in using LC-MS/MS to analyze in vitro, in vivo, and clinical samples through multi-omics approaches. His interests include native protein analysis (protein-ligand and protein-protein interactions via nano- and micro-flow ESI) using both bottom-up and top-down approaches, off-target interactions, metabolomics, lipidomics, proteomics, antibody-drug conjugate (ADC) analysis, identifying posttranslational modifications (PTMs) on biologics, quantitative drug analysis, pharmacokinetics/pharmacodynamics (PK/PD) profiling, drug-drug interaction (DDI) studies, and ADME (Absorption, Distribution, Metabolism, and Excretion) profiling.
Currently a postdoctoral fellow at Harvard Medical School in the Neurosurgery Department, Dr. Amin investigates new drugs and biologics in clinical trials using multi-omics profiling techniques, including lipidomics, metabolomics, metallomics, and proteomics. His research aims to discover better treatments for brain tumors (glioblastoma), other cancers, and neurological diseases.
In The News
-
Do ‘brain training’ apps work? Northeastern scientists will test unique interventions for adolescents with ADHD
Search for a “brain training” application on your smartphone or computer and you will get dozens of suggestions. They all claim to improve memory, attention, problem-solving or other cognitive skills via playing games.